Table of Contents
Baseline characteristics and feasibility of clinical outcome measures in CDKL5 deficiency disorder: The CANDID observational study.
Observational study establishes baseline characteristics and validates clinical assessment tools for CDKL5 deficiency disorder clinical trials.
This study provides the first standardized characterization of CDKL5 deficiency disorder across a large international cohort. It demonstrates that consistent clinical assessment protocols can be implemented across multiple sites for this rare epileptic encephalopathy.
CDKL5 deficiency disorder affects fewer than 1 in 40,000 births, making clinical trial design challenging. This standardized assessment framework creates the infrastructure needed to evaluate emerging gene and enzyme replacement therapies in meaningful clinical trials.
| Study Type | Prospective Longitudinal Observational Study |
| Population | 111 children and adults with CDKL5 deficiency disorder, mean age 8.3 years |
| Intervention | Clinical, behavioral, developmental, and quality of life assessments |
| Comparator | None – descriptive study |
| Primary Outcome | Feasibility and suitability of neurocognitive tests and functioning scales |
| Key Finding | Median seizure onset at 1.5 months, patients averaged 2.6 antiseizure medications, only 6 were seizure-free |
| Journal | Epilepsia |
| Year | 2024 |
The CANDID study establishes that early seizure onset and medication-resistant epilepsy are consistent features of CDKL5 deficiency disorder. The validated assessment tools provide a foundation for measuring treatment efficacy in future clinical trials of novel therapeutics.
This study does not evaluate any therapeutic interventions or demonstrate treatment efficacy. The observational design cannot establish causal relationships or predict which patients might respond to specific treatments.
The abstract provides limited detail about the specific assessment tools used and their validation metrics. Selection bias may exist if only families engaged with research centers participated, potentially missing the most severely affected patients.
This study advances the infrastructure for CDKL5 clinical trials rather than providing therapeutic insights. The consistent early seizure onset and treatment resistance highlight the urgent need for the gene and enzyme replacement therapies currently in development.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
FAQ
What is CDKL5 deficiency disorder and how common is it?
CDKL5 deficiency disorder (CDD) is a rare X-linked developmental and epileptic encephalopathy caused by loss-of-function variants in the CDKL5 gene. It presents with early-onset seizures, severe developmental delays, and significant neurological impairments affecting both children and adults.
When do seizures typically begin in patients with CDD?
According to the CANDID study, seizures in CDD patients typically begin very early in life, with a median onset at 1.5 months of age. The range varied from birth to 66 months, but the majority of patients experience seizure onset within the first few months of life.
How well controlled are seizures in CDD patients?
Seizure control remains challenging in CDD, with the study showing that patients used an average of 2.6 antiseizure medications. Only six patients in the study of 111 were seizure-free, indicating that most patients continue to experience seizures despite treatment.
What is the purpose of the CANDID study?
CANDID is a 3-year longitudinal observational study designed to evaluate and harmonize clinical assessment tools for future CDD clinical trials. The study aims to identify suitable neurocognitive tests and functioning scales that can serve as non-seizure clinical endpoints for evaluating potential therapies like gene therapy or enzyme replacement.
What promising treatments are being developed for CDD?
Preclinical experiments have shown promise for enzyme replacement therapies and gene therapies in CDD models. These approaches could potentially be transformative treatments, which is why establishing standardized clinical assessment tools through studies like CANDID is crucial for future therapeutic trials.
